Compare HRMY & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | SUPN |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.6B |
| IPO Year | 2020 | 2012 |
| Metric | HRMY | SUPN |
|---|---|---|
| Price | $38.97 | $47.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $51.33 | ★ $63.25 |
| AVG Volume (30 Days) | ★ 789.9K | 664.8K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.44 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $825,944,000.00 | $681,539,000.00 |
| Revenue This Year | $23.11 | $8.32 |
| Revenue Next Year | $16.15 | $23.36 |
| P/E Ratio | $12.79 | ★ N/A |
| Revenue Growth | ★ 21.13 | 4.54 |
| 52 Week Low | $25.52 | $29.16 |
| 52 Week High | $40.93 | $57.65 |
| Indicator | HRMY | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 67.08 | 54.34 |
| Support Level | $38.12 | $45.36 |
| Resistance Level | $40.00 | $47.26 |
| Average True Range (ATR) | 1.26 | 1.23 |
| MACD | 0.13 | 0.40 |
| Stochastic Oscillator | 68.68 | 91.91 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.